Sunday, May 21, 2017 8:13:59 PM
The fact that cardiovascular is one of the indications stood out !! That and seeing ANI & Antares two relatively very small Co s & look at the Companies their listed with ! & their in a list that only indicate several Companies speaks volumes
Market Research Report
Global Transdermal Drug Delivery Market Analysis & Opportunity Outlook 2021
Published On : 10:36 PM, 7th May, 2017 REP-ID-111
Category: Healthcare
Preview Analysis
Table of Contents
Ask The Analyst
Customize Request
Transdermal patch is a pharmaceutical paste patch that is positioned on the skin to transport a special amount of medicine through the skin into the blood circulation hence make it non- invasive way of drug delivery. Global transdermal drug delivery market was estimated at USD 22.0 Billion in 2010 and reached to at USD 32.0 Billion in 2015, registering a compound annual growth rate (CAGR) of 8.0%.
Market Segmentation
By Application
Based on the application, global transdermal drug delivery market is segmented are as follows:
Cardiovascular
CNS
Hormone
Pain Management
Others
By Technology
While studying the global transdermal drug delivery market, we had segregated the market into:
Electric current
Electroporation
Lontophoresis
Mechanical arrays
Microporation
Radio Frequency
Thermal
Ultrasound
By Region
On the basis of region, the global transdermal drug delivery market is segmented into:
North America
Latin America
Western And Eastern Europe
Asia-Pacific
Row (Rest Of World)
Growth Drivers and challenges
On the back of factors like rising number of transdermal drug delivery products, enhanced awareness in developed nations about non-invasive way of drug administering drugs into body, increasing demand owing to its convenience over other conventional methods for supervising drugs etc. the transdermal patch drug delivery market is expected to have a greater demand in near future.
In addition to that, steep rise in diabetic population across the globe, advancement of technology in transdermal drug delivery and rise in the personal disposable income across the world are the factors which are anticipated to drive the growth of global transdermal drug delivery market during the forecasted period i.e. 2015-2021.
The global transdermal drug delivery market is restraint by high cost of the product, lack of awareness among in the developing and under-developed countries and availability of various alternatives in the market.
Market Size and Forecast
Global transdermal drug delivery market is estimated at USD 30.3 Billion in 2015 with 12.6% share accounted to the U.S. only; biggest market for transdermal drug delivery in the region. North American total drug delivery market was estimated at USD 518.2 Billion in 2015 and is anticipated to reach USD 752.6 Billion by 2021. Owing to rise in the demand of innovative drug delivery market in this region and growing acceptance of drug delivery technology by pharmaceutical and medical device companies are few of the factors that are projected to drive the transdermal patch drug delivery market in North America.
The European total drug delivery market was valued at USD 39.9 Billion in the year 2012 and it is anticipated that the transdermal drug delivery market will grow at a healthy rate over the forecasted period i.e. 2015-2021 owing to the increasing demand for self-administration and home healthcare devices.
Asia pacific transdermal drug delivery market is projected to grow at a substantial rate owing to a steep rise in medical tourism in the region, world-class medical facilities and medical procedures at a low cost, rising incidents of chronic diseases like cardiovascular diseases, diabetes, cancer etc.
Key Players
The key player of the global transdermal drug delivery market is as follows:
ANI Pharmaceuticals Inc.
Antares Pharma Inc.
Bayer AG
Janssen Pharmaceuticals Inc.
Novartis AG
Scope and Context
Recent ANIP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:03:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 08:50:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 01:13:56 PM
- ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences • GlobeNewswire Inc. • 09/16/2024 12:53:27 PM
- ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences • GlobeNewswire Inc. • 09/16/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 08:23:15 PM
- ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution • GlobeNewswire Inc. • 09/13/2024 10:50:00 AM
- ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger • GlobeNewswire Inc. • 09/11/2024 10:50:00 AM
- ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger • Business Wire • 09/11/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:44:38 PM
- ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences • GlobeNewswire Inc. • 09/10/2024 06:09:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 12:29:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:21:44 PM
- ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes • GlobeNewswire Inc. • 08/13/2024 08:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 01:51:52 AM
- ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering • GlobeNewswire Inc. • 08/08/2024 01:44:18 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:26:24 AM
- ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering • GlobeNewswire Inc. • 08/07/2024 11:00:55 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 10:57:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 10:53:07 AM
- ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance • GlobeNewswire Inc. • 08/06/2024 10:50:00 AM
- ANI Pharmaceuticals to Discuss Second Quarter 2024 Financial Results on August 6, 2024, at 8:30 a.m. ET • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 09:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 09:27:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/18/2024 09:12:40 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM